Review article: panitumumab ‐ a fully human anti‐EGFR monoclonal antibody for treatment of metastatic colorectal cancer

Open Access
Publisher Website
Google Scholar
Abstract
Aliment Pharmacol Ther 28, 269–281 Summary Background Panitumumab is a fully human monoclonal IgG2 antibody targeting the epidermal growth factor receptor (EGFR). Aim To review the efficacy of panitumumab in the treatment of metastatic colorectal cancer (mCRC). Methods Available literature identified from PubMed and conference websites was reviewed. Results In phase 2–3 studies, panitumumab monotherapy achieved objective response rates (ORRs) of 8–13% in relapsed/refractory EGFR‐expressing mCRC. In a randomized phase 3 study (463 patients), panitumumab almost halved the risk of disease progression/death vs. a control group receiving only best supportive care (hazard ratio 0.54; 95% CI: 0.44–0.66; P < 0.0001). Objective response was achieved in 22/231 (10%) patients randomized to panitumumab – and also in 20/176 (11%) patients assigned to the control group who received panitumumab in a separate crossover protocol after disease progression. Response was confined to patients with tumours harbouring wild‐type KRAS (ORR ≈20%). Panitumumab is also being evaluated in earlier lines of treatment. Panitumumab monotherapy is generally well tolerated; the most common toxicities are skin toxicity (≈90%) and diarrhoea (KRAS.

This publication has 62 references indexed in Scilit: